Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Jan 25:15:1322152.
doi: 10.3389/fimmu.2024.1322152. eCollection 2024.

Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion

Ju-Li Lin #  1   2 , Mi Lin #  1   2 , Guang-Tan Lin  1   2 , Qing Zhong  1   2 , Jun Lu  1   2 , Chao-Hui Zheng  1   2 , Jian-Wei Xie  1   2 , Jia-Bin Wang  1   2   3 , Chang-Ming Huang  1   2   3 , Ping Li  1   2   3
Affiliations
Comment

Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion

Ju-Li Lin et al. Front Immunol. .

Abstract

Objective: To explore the oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion.

Methods: This study is a retrospective cohort study and retrospectively analyzed the clinicopathological data of 128 patients with serosal invasion gastric cancer (cT4NxM0) who received nab-paclitaxel + S-1(SAP) or camrelizumab + nab-paclitaxel + S-1 (C-SAP) regimen and underwent laparoscopy assisted gastrectomy in Fujian Union Hospital from March 2019 to December 2020. The patients were divided into SAP group and C-SAP group. The 2-years overall survival rate, 2-year recurrence free survival rate recurrence rate and initial recurrence time were compared between the two groups.

Results: A total of 128 patients were included, including 90 cases in SAP group and 38 cases in C-SAP group. There were no significant differences in age, gender, gastrectomy method, surgical approach, R0 resection, nerve invasion, vascular invasion, total number of harvested lymph nodes, number of positive lymph nodes and major pathologic response (MPR) rate between the two groups (P>0.05). However, the proportion of ypT0, ypN0 and pCR rate in C-SAP group were significantly higher than those in SAP group (P<0.05). The 2-year OS of C-SAP group (80.7%) was higher than that of SAP group (67.8%), and the difference was not statistically significant (P = 0.112); At 2 years after operation, the recurrence rate of C-SAP group (44.3%) was lower than that of SAP group (55.8%) (P = 0.097); Further analysis showed that the average time to recurrence in the C-SAP group was 18.9 months, which was longer than that in SAP group 13.1 months (P = 0.004); The 2-year recurrence free survival rate in C-SAP group was higher than that in SAP group (P=0.076); There was no significant difference in the overall survival time after recurrence between the two groups (P= 0.097).

Conclusion: Camrelizumab combined with neoadjuvant chemotherapy can improve the proportion of ypT0, ypN0 and pCR in patients, while prolonging the initial recurrence time of patients in the C-SAP group, but did not increase the immunotherapy/chemotherapy related side effects and postoperative complications.

Keywords: 2-year recurrence free survival rate; 2-years overall survival rate; Camrelizumab; Gastric cancer with serous invasion; Neoadjuvant chemotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
(A) the 2-years overall survival rate of C-SAP group (80.7%) was higher than that of SAP group (67.8%) (P=0.112). (B) In M0 patients, the 2-years overall survival rate of C-SAP group (79.9%) was similar to that of SAP group (71.9%) (P=0.703). (C) In M1 patients, the 2-years overall survival rate of C-SAP group (85.7%) was significantly better than that of SAP group (0%)(P =0.002,).
Figure 2
Figure 2
The 2-year recurrence free survival rate of C-SAP group (62.0%) was higher than that of SAP group (46.2%)(P=0.361).
See this image and copyright information in PMC

Comment on

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin (2021) 71(3):209–49. doi: 10.3322/caac.21660 - DOI - PubMed
    1. Lin JL, Lin JX, Lin JP, Zheng CH, Li P, Xie JW, et al. . Safety and efficacy of camrelizumab in combination with nab-paclitaxel plus S-1 for the treatment of gastric cancer with serosal invasion. Front Immunol (2021) 12:783243. doi: 10.3389/fimmu.2021.783243 - DOI - PMC - PubMed
    1. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. . Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol (2018) 4(5):e180013. doi: 10.1001/jamaoncol.2018.0013 - DOI - PMC - PubMed
    1. AJCC Cancer Staging Manual, 8th Edition (2020), Definitions. U.S. New York: Springer.
    1. Li Z, Shan F, Ying X, Zhang Y, E JY, Wang Y, et al. . Assessment of laparoscopic distal gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: A randomized clinical trial. JAMA Surg (2019) 154(12):1093–101. doi: 10.1001/jamasurg.2019.3473 - DOI - PMC - PubMed

Publication types